In other studies, from Norway (190 BOT and 478 ovarian cancer patients) and Canada (134 BOT and 515 ovarian cancer patients), the BRCA1/2 mutations were detected in 4% and 11.7% invasive cases, respectively, but none of the patients with BOT [12, 13]. This evidence concerns the gene BRCA1 and ovarian carcinoma.